의료기기 이야기

BackgroundThe Medical Device Coordination Group (MDCG) has issued an update to the European vigilance guidance MDCG 2023-3. The document now covers devices regulated under the IVDR. As Emergo by UL reported last year, the initial version of MDCG 2023-3 explicitly excluded IVDs from its scope. Guidance on vigilance reporting for IVDsThe guidance now includes IVD-specific examples of incidents, se..

Medical device manufacturers selling in the European market will want to take note of the compliance requirements of several new guidance documents. It has been a busy October month for the European Commission (EC) and for stakeholders participating in the relevant Medical Devices Coordination Groups (MDCG). With the adoption of Regulation (EU) 2024/1860, not only the transitional timelines for ..

Background In Jan. 2024, the U.K. medical device regulator, the MHRA, shared a roadmap detailing how it planned to implement future medical device regulations. In September 2024, Dr. Robert Reid, Deputy Director, MHRA, Innovative Device, provided attendees at the RAPS Convergence with an update on that roadmap.On Nov. 1, Dr. Laura Squire, Chief Healthcare Quality and Access Officer, MHRA, publis..

Emergo에서 아래와 같이 웨비나를 개최한다.​▶ 주제: The Role of AI in the Practice of Human Factors Engineering▶ 일시: 2024년 11월 20일 CST 9시 (한국시간: 11월 21일 00시) During this webinar, the presenters will briefly discuss the various medical technologies that incorporate AI features and/or machine learning. However, the focus will be on how AI of the chatbot variety can facilitate a wide range of analyses and writing eff..

It has caused years and years of regulatory uncertainty: Which EU law regulates ethylene oxide (EtO) used for sterilization of medical devices? At least for medical device and IVD manufacturers, this should be clear by now, with the publication of “MDCG 2024-13 Regulatory status of ethylene oxide (EtO) intended for the sterilization of medical  devices”.  What the MDCG document regulating steril..

The demand for medication to be delivered using autoinjectors is rising internationally, responding to the increased incidence rates of chronic conditions and the emerging treatments for those chronic conditions. Autoinjectors are used to deliver medication to treat Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Crohn’s Disease, among others. It is reasonable to assume that some autoinje..

Draft requirements for post-market surveillance (PMS) of medical devices in the U.K. align closely with European regulations, but not entirely. Below, Emergo by UL continues our analysis of the proposed legislation. As noted in a previous Regulatory Update, a draft post-market surveillance statutory instrument (PMS SI) was laid in the U.K. Parliament (October 21) to introduce new PMS and vigilan..

BackgroundFollowing the publication of the draft PMS SI on the World Trade Organization (WTO) website on July 26, 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) has, after considering stakeholder responses to that draft, published the “final” draft PMS SI. This instrument introduces new PMS requirements for medical devices that improve patient safety by establishing stricte..

You might have heard some rumors already: Several European parliamentarians sent a joint motion for resolution to the European Commission (EC). On October 21st, 2024, a European Parliament resolution “on the urgent need to revise the Medical Devices Regulation” (2024/2849(RSP)) was submitted to the EC. In addition, the Heads of Medicines Agencies (HMA, heads of EU Competent Authorities responsib..

BackgroundIn recent years, the TGA has enacted several reforms to advance regulatory harmonization or reliance. Manufacturers are able to leverage existing conformity assessment evidence issued by a comparable overseas regulator or assessment body as the Manufacturer Evidence to support an application to add a medical device or IVD to the Australian Register of Therapeutic Goods (ARTG). Further ..